Data as-of 2026-07-24 close (Friday settled close).

TMO crossed into overbought this week — RSI 71.0, the only name in this 39-ticker cut above the 70 threshold, even as its thesis stays flagged "intact." At the other end, IONS — the sector's lone sub-25 print two scans ago — climbed back to RSI 32.7, still down -26.1% over the past 30 days but no longer in free fall. The bigger story is a rotation: DHR (65.7 → 50.4) and PTGX (69.0 → 60.0), last scan's two steadiest large caps, both cooled hard, while ISRG stayed pinned in a collapse regime at RSI 31.4, -45.0% off its 52-week high. Thirteen of the 39 names now sit in the 25-40 oversold band — the widest spread in recent scans — though for the first time in a while nothing prints below 25.

Source: biotech-scan.json. Latest bar 2026-07-24 for every name in this cut. Prior scan: 2026-07-17-biotech-scan.

TMO is the session's clearest single-name story. RSI climbed to 71.0 — the only name in this cut above the overbought threshold — on a +6.72% week and +15.45% 30-day gain (change7d, change30d per biotech-scan.json), while the thesis flag still reads "intact." That combination (extended technicals, unchanged fundamental read) is worth a second look next cycle rather than an automatic add at current levels.

ISRG remains the sector's most structurally broken large-cap. RSI sits at 31.4, essentially unchanged from the 30.2 flagged two scans ago, but the price keeps deteriorating: -45.02% off its 52-week high, worse than the -42.8% read on July 17, with the regime classifier still reading "collapse" despite an "intact" thesis flag on file.

The gene-editing cohort split rather than moving together this time. NTLA (RSI 30.5) and CRSP (36.3) are essentially flat versus two scans ago, LEGN improved (27.9 → 31.1), but EDIT (46.4 → 36.6) and BEAM (34.8 → 31.8) both got worse. That's a break from the pattern flagged on July 17, when the whole group — NTLA, CRSP, RXRX, LEGN — moved down together.

Two names had the roughest single sessions in the cut: DNA dropped -7.19% in one day, and LEGN fell -5.57% in a single session (change1d per biotech-scan.json). Neither move shows up as a clean reversal signal yet — both remain in weaker technical regimes.

• TMO pushed into overbought. RSI 62.3 → 71.0, +15.45% over 30 days — the only name in the cut now above the 70 threshold, thesis still marked "intact."
• IONS recovered from the sector's only sub-25 print. RSI 23.9 → 32.7, though still -26.1% over 30 days and the regime classifier still reads "collapse."
• DHR and PTGX, last scan's steadiest large caps, both cooled hard. DHR: RSI 65.7 → 50.4. PTGX: RSI 69.0 → 60.0. Neither is broken, but both gave back their standout status.
• The gene-editing cohort diverged instead of moving together. LEGN improved (27.9 → 31.1); NTLA (30.5 → 30.5) and CRSP (36.2 → 36.3) held flat; EDIT (46.4 → 36.6) and BEAM (34.8 → 31.8) worsened.
• A (Agilent) posted the biggest positive move in the cut. RSI 50.3 → 61.4, +20.15% over 3 months, +5.41% over the past week.
• Broad biotech ETF proxies cooled. XBI: 55.1 → 48.6. IBB: 58.4 → 53.7. IBBQ: 57.9 → 52.5.
• REGN, GILD, DXCM, KYMR, NVO all cooled from prior extension into the RSI 48-54 band, down from the high-50s/60s two scans ago.
• ABBV held its leadership position. RSI 65.9 → 67.4, still not extended vs the group.
• Universe unchanged. Same 39 tickers as the July 17 cut — no entrants or dropouts.

RSI measures how stretched a stock is over the past 14 sessions — under 30 signals oversold, over 70 signals overbought/extended. vs SMA20 is the price gap to the 20-day average; a large negative number means a fast recent decline. vs VWAP is the premium (or discount) versus the average price paid by everyone still holding — a big positive number means most of a name's move is unrealized gain that can get sold into weakness. Trend pairs direction/strength with a cross signal: GC (golden cross, the short-term average above the long-term average) is structurally healthier than DC (death cross). A stock at a low RSI while still marked strong-down DC or in a "collapse" regime — like ISRG here — is not a confirmed buy signal; it means the price is cheap relative to its own recent range, not that the structure has turned.

None. For the first time in several scans, nothing in this cut is below 25 — IONS, the sole sub-25 print last scan, has climbed to 32.7.

NTLA (30.5), LEGN (31.1), ISRG (31.4), BEAM (31.8), IONS (32.7), DNA (35.3), SRPT (35.5), CRSP (36.3), EDIT (36.6), MRNA (36.7), RARE (37.6), RXRX (38.9), ALNY (39.3). Thirteen names — the widest spread of any recent scan — split between deteriorating positions (BEAM, EDIT, DNA) and names showing early relief (IONS, LEGN).

• Still cooling (RSI 41-49): BNTX, LABU, DXCM, GILD, XBI, VRTX. None broken, but all pulled back from a stronger prior read.
• Basing / cleanest accumulate (RSI 50-58): DHR, BIIB, REGN, IBBQ, NVO, IBB, KYMR, NKTR, MDT, BMRN, LLY, COGT. AMGN and ABBV are the standouts just above this band — never got extended.
• Momentum, holding not adding (RSI 60+): PTGX, A, ILMN, IQV, INCY, AMGN, ABBV, TMO. TMO alone crossed the overbought line at 71.0.

• Does TMO's push into overbought resolve as a normal cool-off, or does the thesis-intact large-cap keep running?
• IONS climbed off the sector's only sub-25 print to 32.7 this week — does that turn into a confirmed reversal, or is the "collapse" regime still the more accurate read?
• DHR and PTGX, last scan's two steadiest large-cap holds, both cooled hard — is this a normal pullback inside an intact uptrend, or the start of something bigger?
• The gene-editing cohort split rather than moving together this scan (LEGN better, EDIT/BEAM worse) — does it re-converge, or is this the start of genuine dispersion within the group?

• Tape data (price/RSI/SMA/returns): full-scan pre-computed summaries as of the 2026-07-24 close — biotech-scan.